Press release
Esophageal Squamous Cell Carcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA | BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co.
Explore our latest breakthroughs in Esophageal Squamous Cell Carcinoma Research. Learn more about our innovative pipeline today! @ Esophageal Squamous Cell Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Esophageal Squamous Cell Carcinoma Pipeline Report
* June 2024:- Sichuan Baili Pharmaceuticals- Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 Combined With Irinotecan in the Treatment of Recurrent and Metastatic Esophageal Squamous Cell Carcinoma. This multi-center, open label Phase II clinical study is performed in patients with relapsed and metastatic esophageal squamous cell carcinoma progressed on prior PD-1/L1 antibody with or without chemotherapy. This study is investigating the safety and efficacy of SI-B001 at optimal combination dose with irinotecan in patients.
* DelveInsight's Esophageal Squamous Cell Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Esophageal Squamous Cell Carcinoma treatment.
* The leading Esophageal Squamous Cell Carcinoma Companies such as BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc., and others.
* Promising Esophageal Squamous Cell Carcinoma Therapies such as Camrelizumab, SI-B001, Irinotecan, Paclitaxel, Cisplatin, JMT101, and others.
Stay informed about the cutting-edge advancements in Esophageal Squamous Cell Carcinoma Treatments. Download for updates and be a part of the revolution in oncology care @ Esophageal Squamous Cell Carcinoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Esophageal Squamous Cell Carcinoma Emerging Drugs Profile
* Tislelizumab: BeiGene
Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcR on macrophages. In pre-clinical studies, binding to FcR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug candidate produced from BeiGene's immuno-oncology biologic program, and we believe it could serve as a key element of our immuno-oncology combination platform. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. Currently, it is in Phase III stage of clinical trial evaluation to treat Esophageal Squamous Cell Carcinoma.
* Serplulimab: Shanghai Henlius Biotech
Serplulimab (novel anti-PD-1 mAb) is the first innovative monoclonal antibody (mAb) developed by Henlius. Shanghai Henlius Biotech, announced that the phase 3 clinical study ASTRUM-007 of HANSIZHUANG (serplulimab) independently developed by the company in combination with chemotherapy as a first-line treatment for patients with locally advanced/metastatic esophageal squamous cell carcinoma (ESCC), met the co-primary endpoints of progression-free survival (PFS) and overall survival (OS) in a planned interim analysis, evaluated by the Independent Data Monitoring Committee (IDMC).
Learn more about Esophageal Squamous Cell Carcinoma Drugs opportunities in our groundbreaking Esophageal Squamous Cell Carcinoma Research and development projects @ Esophageal Squamous Cell Carcinoma Unmet Needs [https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Esophageal Squamous Cell Carcinoma Companies
BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc., and others.
Esophageal Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Inhalation
* Inhalation/Intravenous/Oral
* Intranasal
* Intravenous
* Intravenous/ Subcutaneous
* NA
* Oral
* Oral/intranasal/subcutaneous
* Parenteral
* Subcutaneous
Esophageal Squamous Cell Carcinoma Products have been categorized under various Molecule types such as
* Antibody
* Antisense oligonucleotides
* Immunotherapy
* Monoclonal antibody
* Peptides
* Protein
* Recombinant protein
* Small molecule
* Stem Cell
* Vaccine
Discover the latest advancements in Esophageal Squamous Cell Carcinoma Treatment by visiting our website. Stay informed about how we're transforming the future of oncology disease @ Esophageal Squamous Cell Carcinoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Esophageal Squamous Cell Carcinoma Pipeline Report
* Coverage- Global
* Esophageal Squamous Cell Carcinoma Companies- BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc., and others.
* Esophageal Squamous Cell Carcinoma Therapies- Camrelizumab, SI-B001, Irinotecan, Paclitaxel, Cisplatin, JMT101, and others.
* Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Esophageal Squamous Cell Carcinoma Pipeline on our website @ Esophageal Squamous Cell Carcinoma Drugs and Companies [https://www.delveinsight.com/sample-request/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Esophageal Squamous Cell Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Esophageal Squamous Cell Carcinoma - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Tislelizumab: BeiGene
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* RAPA-201: Rapa Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* SGN-B6A: Seagen
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Esophageal Squamous Cell Carcinoma Key Companies
* Esophageal Squamous Cell Carcinoma Key Products
* Esophageal Squamous Cell Carcinoma- Unmet Needs
* Esophageal Squamous Cell Carcinoma- Market Drivers and Barriers
* Esophageal Squamous Cell Carcinoma- Future Perspectives and Conclusion
* Esophageal Squamous Cell Carcinoma Analyst Views
* Esophageal Squamous Cell Carcinoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=esophageal-squamous-cell-carcinoma-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-beigene-shanghai-henlius-biotech-cstone-pharmaceuticals-jiangsu-hengrui-medicine-co]
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Esophageal Squamous Cell Carcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA | BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co. here
News-ID: 3564795 • Views: …
More Releases from ABNewswire
Self-healing Networks Market Latest Trends, Outlook, Size, Share, Applications, …
Self-healing Networks Market by Component (Solutions, Services), Network Type (Public, Private, & Hybrid), Application (Network Provisioning, Network Traffic Management), Vertical (Telecom, Healthcare & Life Sciences) and Region - Global Forecast to 2027.
The self-healing networks market [https://www.marketsandmarkets.com/Market-Reports/self-healing-networks-market-196310163.html?utm_campaign=selfhealingnetworksmarket&utm_source=abnewswire.com&utm_medium=referral] is expected to increase at a compound annual growth rate (CAGR) of 33.3% from USD 0.6 billion in 2022 to USD 2.4 billion by 2027. Over the course of the forecast period, the self-healing…
Pine Monte Premium Candles Elevates Texas Home Fragrance Market with Veteran-Own …
Pine Monte Premium Candles LLC, a veteran-owned business in Katy, Texas, is transforming the home fragrance industry with handcrafted, small-batch candles made from 100% soy wax. The company combines artisanal quality with carefully curated fragrance blends to deliver cleaner burns and elevated sensory experiences for candle enthusiasts across Texas and beyond.
Katy, Texas has become home to a growing artisan movement, and Pine Monte Premium Candles LLC stands at the forefront…
AppleMango Trading Co Raises the Bar for Authentic Designer Fragrances in Online …
AppleMango Trading Co, LLC, a trusted online retailer specializing in 100% authentic designer fragrances, announces its commitment to providing consumers with verified, U.S.-compliant products backed by a fully documented supply chain. Operating through its Shopify-based e-commerce platform, the company serves customers seeking genuine brand-name scents with complete transparency and reliability.
In an era where counterfeit fragrances flood online marketplaces and erode consumer confidence, AppleMango Trading Co, LLC stands apart as a…
SingleTree Lane Challenges Fashion's Power Imbalance as a Black Female-Owned Wea …
SingleTree Lane, an up and coming wearable-art fashion brand founded and led by a Black female creative, announces its continued expansion as a self-funded, independent fashion house built outside the industry's traditional power structures.
In an industry where the most profitable apparel empires are overwhelmingly male-led-and female-led brands are disproportionately white-SingleTree Lane stands as a rare and necessary counterexample: a Black-owned brand achieving international recognition without venture capital, celebrity investors, or…
More Releases for Cell
Cell Sorting Market Accelerates as Cell Therapy, Immuno-Oncology & Single-Cell R …
The rising focus on precision medicine, immunotherapy, and advanced cell-based research is driving the global cell sorting market into a high-growth phase. With expanding applications in stem cell therapy, CAR-T manufacturing, cancer immunology, and single-cell genomics, demand for accurate, high-purity cell isolation systems is stronger than ever. This release highlights key market trends, segmentation insights, technological innovations, and the factors shaping the future of cell sorting.
Download Full PDF Sample Copy…
Cell Isolation Cell Separation Market Size Analysis by Application, Type, and Re …
According to Market Research Intellect, the global Cell Isolation Cell Separation market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The market for cell isolation and separation is expanding rapidly as a result of sophisticated biotechnological…
Cell Free Protein Synthesis Market Beyond the Cell: Revolutionizing Protein Prod …
Cell-Free Protein Synthesis Market to reach over USD 457.13 Mn by the year 2031 - Exclusive Report by InsightAce Analytic
"Cell-Free Protein Synthesis Market" in terms of revenue was estimated to be worth $265.94 Mn in 2023 and is poised to reach $457.13 Mn by 2031, growing at a CAGR of 7.20% from 2024 to 2031 according to a new report by InsightAce Analytic.
Request for free Sample Pages: https://www.insightaceanalytic.com/request-sample/1445
Current…
Cell Expansion Market - Expand the Boundaries of Cell Therapy: Redefine Cell Exp …
Newark, New Castle, USA: The "Cell Expansion Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Cell Expansion Market: https://www.growthplusreports.com/report/cell-expansion-market/7939
This latest report researches the industry structure, sales, revenue,…
Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect …
Researchmoz added Most up-to-date research on "Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect Cell and Others" to its huge collection of research reports.
This report researches the worldwide GMP Cell Banking market size (value, capacity, production and consumption) in key regions like North America, Europe, Asia Pacific (China, Japan) and other regions.
This study categorizes the global GMP Cell Banking breakdown data by manufacturers, region, type…
Cell Culture Market Size, Cell Culture Market Share, Cell Culture Market Trends …
According to a new research published by Polaris Market Research the global cell culture market is anticipated to reach more than USD 49 billion by 2026. Cell culture is a rapidly emerging as an implement for analyzing and treating various disease such as Alzheimer’s and cancer.
Request for Sample of This Research Report @ https://bit.ly/2D7pZ5u
Top Key Players: -
Becton,
Dickinson and Company
Biospherix
EMD Millipore
Eppendorf AG
Merck KGaA
Sartorius AG
VWR International
Cell culture is a rapidly emerging…
